Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

Author's Avatar
Aug 31, 2022

Janux+Therapeutics%2C+Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate and present at two upcoming investor conferences. Details are as follows: